Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of tranexamic acid in cytoreductive surgery for ovarian cancer

Conditions: Advanced Ovarian Cancer

Summary: tranexamic acid has been used in surgery for more than 30 years. it's effect on reducing bleeding and blood transfusing has been demonstrated. in our hospital, the amount of cytorsductive surgery for ovarian cancer is big. during the perioperation , bleeding probability is high, and the supply of blood products is limited. in order to reduce bleeding, we're planning to use tranexamic acid in the operations. in this experiment, we will observe the efficacy of tranexamic acid in cytoreductive surgery for ovarian cancer, find the best dosage which can reach the desired effect, and the possible side-effect.

we performed a single blind, prospective, randomised control trial (rct) . the patients randomised assigned to three groups. low dose txa, high dose txa or a placebo of iv saline which will be infused prior to skin incision in patients undergoing elective cytorsductive surgery for ovarian cancer . intraoperative blood loss will be estimated by the volume in the suction drains and by weighing the swabs. postoperative blood loss will be estimated by the volume in the drains. the other secondary outcomes will be inclued perioperation transfusion volume, thromboembolic complications, icu length of stay (los), hospital los, adverse thrombogenic events within 30 days, 30-day all-cause readmission and so on.

Eligibility criteria:
inclusion criteria: 1. sign the informed consent 2. aged 20-70 years 3. ovarian cancer patients, staged iiib - c or above 3) asa i - ii exclusion criteria: 1. tranexamic acid allergy 2. pregnancy and lactation 3. only lymph node metastasise 4. history of mental disorder, immune system disorder 5. history of epilepsy, dyschromatopsia 6. arrhythmia 7. history of renal insufficiency 8. thrombosis related disease 9. hb \< 90 g/dl 10. using anticoagulant drugs (not including aspirin discontinuation 1 week 11. having participated in other clinical trials, or refusing to join the research.
eye-cervical re-education versus motor imagery therapy on proprioception in chronic mechanical neck pain

Conditions: Neck Pain

Summary: this study will be conducted to investigate the effect of eye-cervical re-education versus motor imagery therapy on pain intensity level, pain pressure threshold, neck disability, cervical proprioception, and scapular protraction in patients with chronic mechanical neck pain.

chronic neck pain is a common problem in modern and industrialized countries and among employed individuals. pain is classified as chronic neck pain persists for more than 3 month, it may be felt all the time or worsen with certain activities. the cervical spine has an important role in providing the proprioceptive input and this is reflected in the abundance of cervical mechanoreceptors and their central and reflex connections to the vestibular, visual, and central nervous systems. eye-cervical re-education program (ecrp) refer to a therapeutic procedure for correcting posture cephalic level in patients with cervical pain by improving eye-neck proprioception that reduced symptoms experienced by patients and improvement of the quality of cervical afferent input into the central nervous system. motor imagery is the mental realization of motion without any motion occurs. it has two categories: kinesthetics and visual imagery. kinaesthetic imagery is the situation of feeling a motion. visual imagery has two types: internal visual and external visual. in the internal visual imagery, the motion is visualized within the body by seeing feet and arms. the external visual imagery is that one sees himself/herself from outside. one hundred and twenty patients will be allocated randomly into three groups; group a will receive eye cervical re-education and conventional therapy, group b will receive motor imagery therapy and conventional therapy and group c will receive conventional therapy only three times a week for four weeks.

Eligibility criteria:
inclusion criteria: 1. age will range from 18 to 70 years 2. patients of both sexes. 3. neck pain diagnosed by physician greater than 3 months in duration. 4. active or latent myofascial trigger points (mtrps) in at least one of the following muscles: upper trapezius, levator scapulae, or splenius capitis. both active and latent mtrps were considered because latent mtrps have been associated with the development of sensory motor dysfunction and may contribute to different chronic musculoskeletal pain disorders exclusion criteria: 1. dizziness syndrome. 2. post-traumatic as whiplash 3. neurological, infectious, or tumor cervical pain. 4. pregnant women. 5. patients having speech and understanding problems. 6. past history of neck surgery 7. dizziness syndrome. 8. post-traumatic as whiplash. 9. neurological, infectious, or tumor cervical pain. 10. pregnant women. 11. patients having speech and understanding problems. 12. past history of neck surgery .

Keywords: eye-cervical re-education motor imagery therapy neck pain
safety and efficacy of eculizumab in refractory generalized myasthenia gravis (regain study)

Conditions: Refractory Generalized Myasthenia Gravis

Summary: the purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized myasthenia gravis.


Eligibility criteria:
key inclusion criteria: * male or female patients ≥18 years old * diagnosis of mg made by the following tests: 1. positive serologic test for anti-achr abs as confirmed at screening, and 2. one of the following: 1. history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (sfemg) or repetitive nerve stimulation, or 2. history of positive anticholinesterase test, e.g. edrophonium chloride test, or 3. subject has demonstrated improvement in mg signs on oral cholinesterase inhibitors, as assessed by the treating physician. * mgfa clinical classification class ii to iv at screening. * mg-adl total score must be ≥6 at screening and randomization (day 1). * subjects who have: 1. failed treatment with at least two immunosuppressive agents. or, 2. failed treatment with at least one immunosuppressive agent and require chronic plasma exchange or ivig key exclusion criteria: * history of thymoma or other neoplasms of the thymus * history of thymectomy within 12 months prior to screening * mgfa class i or mg crisis at screening (mgfa class v) * use of rituximab within 6 months prior to screening * use of ivig or pe within 4 weeks prior to randomization (day 1)

Keywords: myasthenia gravis eculizumab safety efficacy
duration of infusion set function: quick-set teflon catheter versus sure-t steel infusion set catheter

Conditions: Diabetes Mellitus

Summary: this is an open-label cross over study looking to compare the length of infusion set wear between a teflon catheter (quick-set) or a steel (sure-t) catheter.

currently infusion sets are approved for 2-3 days of wear. in this study subjects will wear each infusion set for up to 7 days or until the infusion set fails. subjects will alternate between wearing the quick-set teflon catheter and the sure-t steel catheter each week. they will wear each infusion set twice. for the study, subjects will be provided with an investigational medtronic real-time continuous glucose monitor (cgm) enlite sensor/serter to help identify, serious hyperglycemia or hypoglycemia during the study. this sensor is not yet fda approved, but is similar to commercially available sensors. if the sensor detects a high or low glucose, subject must obtain a fingerstick glucose to confirm the result. in the study, all insulin dose and other treatment decisions will be made using glucose meter results, and will not be based on sensor results. subjects will be instructed on how to identify infusion set failures. infusion set failure are defined as: 1) blood ketones greater than 0.6 mmol/l, 2) evidence of infection at the infusion site (such as redness of more than 4 mm), or 3) blood glucose that does not decrease by at least 50 mg/dl within 1 hour of a correction bolus to treat a blood glucose greater than 300 mg/dl. subjects will follow-up weekly in one of our test centers for a total of five visits. at home subjects will be asked to keep a log recording measurements of redness and induration at the infusion site when it is changed prior to the study visit.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 3 months * the diagnosis of type 1 diabetes is based on the investigator's judgment; c peptide level and antibody determinations are not needed. * age 12 to 45 years * for females, not currently known to be pregnant * an understanding of and willingness to follow the protocol and sign the informed consent * hemoglobin a1c level less than or equal to 10% * medtronic continuous subcutaneous insulin infusion pump * must be able to understand spoken or written english exclusion criteria: * diabetic ketoacidosis in the past 6 months * severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment * current treatment for a seizure disorder * cystic fibrosis * active infection * a known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian) * presence of a known adrenal disorder * if on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study * abuse of alcohol
a study to evaluate the safety and effectiveness of a nasal spray to treat seasonal allergies

Conditions: Seasonal Allergic Rhinitis

Summary: the purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than placebo alone.


Eligibility criteria:
inclusion criteria: * male and female patients 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis. * must be in generally good health * must meet minimum symptom requirements, as specified in the protocol * must be willing and able to provide informed consent and to participate in all study procedures * positive skin test to a prevalent texas mountain cedar allergen exclusion criteria: * on focused nasal examination, the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation at either the screening visit or randomization visit will disqualify the subject from the study. * other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal structural abnormalities. * nasal surgery or sinus surgery within the previous year. * chronic sinusitis - more than 3 episodes per year * planned travel outside of the study area during the study period * the use of any investigational drug within 30 days prior to screening. no investigational products are permitted for use during the conduct of this study * presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (splenda® brand sweetener) * women who are pregnant or nursing * women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception * respiratory tract infections within 14 days prior to screening * respiratory tract infections requiring antibiotic treatment 14 days prior to screening * asthma (with the exception of mild, intermittent asthma). subjects with mild, intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment * significant pulmonary disease including copd * clinically significant arrhythmia or symptomatic cardiac conditions * a known history of alcohol or drug abuse within the last 2 years * existence of any surgical or medical condition or physical or laboratory findings, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial. * clinically relevant abnormal physical findings which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
exercise and diet restriction on cardiovascular function in obese children and adolescents

Conditions: Childhood Obesity; Adolescent Obesity

Summary: prevalence rates of childhood obesity have reached alarming levels. as childhood obesity may already be associated with serious comorbidities, obese adolescents are at significantly higher risk for obesity and increased morbidity and mortality during adulthood. combined lifestyle interventions, which include regular physical activity and dietary restriction, have been shown to result in most significant improvements in cardiovascular function and their associated factors in the pediatric and adolescent population with obesity. the aim of this study is to investigate the effects of a combined exercise and diet intervention on cardiovascular function and their associated factors in obese children.

sixty obese children and adolescents will complete a 6-week program of exercise and diet intervention. thirty normal-weight children and adolescents will be recruited as control group. clinical characteristics, body composition, blood biochemistry, and circulating irisin levels of the subjects will be measured before and after 6-week intervention. endothelial function will be assessed by a flow-mediated dilation test. circulating exosome-derived mirnas, exercise-induced epigenetic modifications, circulating irisin levels irisin concentration in plasma and arterial stiffness as well as cardiac autonomic function will be investigated before and after the 6-week intervention. fecal samples were collected before and after the 6-week intervention for analysis of the compositional and functional changes in the human gut microbiota.

Eligibility criteria:
inclusion criteria: 1. participants aged 7-17 years 2. participants satisfied the obesity diagnosis criteria is based on "body mass index reference standards for the screening of overweight and obesity in chinese children and adolescents" released in 2004, with cut-off points of p(95) for obesity exclusion criteria: 1. metabolic disease 2. gastrointestinal disease 3. cardiac disease 4. taking medications which affected energy expenditure 5. losing weight in the past three months whether by diet, taking weight-loss medication or more physical exercise than normal
waiting room's environment and children anxiety prior dental treatment

Conditions: Dental Anxiety

Summary: the amount of time the patient has spent awaiting treatment and the nature of the waiting room environment influence the anxiety level prior treatment. the objective of the present study is to compare the effect of waiting room's environment on the levels of anxiety experienced by children, in sensory adapted dental environment (sade) and traditional waiting rooms. a parallel randomized trial. the participants will be randomly assigned to one type of waiting room. the participants will be asked to answer venham picture test (vpt) scale while waiting in the waiting room just before entering the clinic.

the sade waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. all ceiling fluorescent lighting is removed. the adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, and a lighting column that children can touch and climb on. auditory stimuli include rhythmic music, which is heard via loudspeakers. the traditional waiting room: a waiting area outside the clinic with ten seats in one row faces the reception desk in an area of 15 square meters. the area is air-conditioned, moderately well-lit, without posters or paintings on the walls, and no reading material. •dental anxiety scale- venham picture test (vpt) is widely used and easily administered. in this test, children are presented with eight cards, with two figures on each card, one 'anxious' figure and one 'nonanxious' figure. they are asked to choose the figure from each pair that describes how they feel at that particular time. all cards are shown in their numbered order. if an anxious figure is chosen, a score of one is recorded. if a nonanxious cartoon is chosen, a score of zero is recorded. a measure of anxiety is obtained by totaling the number of times the child picks the cartoons depicting the anxious state (minimum score, 0; maximum score, 8). the participants will be asked to answer while waiting in the waiting room just before entering the clinic. study design- the study is a parallel randomized trial. the participants will be randomly assigned to one type of waiting room. additional data- gender, age, the lengths of waiting, the purpose of the visit (examination or treatment with/without sedation), dental experience, type of waiting room, child escort.

Eligibility criteria:
inclusion criteria: healthy 3-10 years old boys and girls exclusion criteria: mentally unable to understand and answer the venham picture test (vpt) to assess anxiety before treatment, accepted immediately without waiting.
osteoplasty in conjunction with surgical treatment of mandibular grade iii furcation defects (furc-iii-ost)

Conditions: Furcation Defects; Periodontal Diseases

Summary: teeth with furcation grade iii defects will be treated with open flap debridement, with or without osteoplasty. the study is designed to examine the effect of osteoplasty in the treatment of teeth with furcation grade iii defects with open flap debridement.


Eligibility criteria:
inclusion criteria: * periodontal disease stage iii or iv according to 2018 criteria * undergoing periodontal therapy (active or supportive) and present 1 or more pair of bilateral mandibular molars affected by furcation involvement grade iii with ppd\>4mm, and the furcation fornix must be above a tangential line from the distal to mesial interproximal crestal bone level on bitewing radiographs * competent to give consent exclusion criteria: * previous radiotherapy to the jaws, current use of chemotherapy, systemic long-term corticosteroid treatment * present or past use of bisphosphonate treatment * pregnant or nursing subjects * patients classified as \> class ii according to asa classification * previous surgical therapy of included furcation defects * inhability to comprehend and respond to the quality of life questionnaire * dental restorations or prosthesis involving the furcation area * root fractures or suspected fractures/infractions * caries lesoins in the furcation area * no systemic antibiotic treatment within 3 months prior to intervention
honest open proud for adolescents with mental illness

Conditions: Secrecy Versus Disclosure Among Adolescents With Mental Illness

Summary: the purpose of the study is to evaluate the efficacy of the group-based intervention 'honest open proud' among adolescents with mental illness.

both due to fear of public stigma and due to self-stigma or shame, people with mental illness may decide to keep their condition a secret or even to withdraw from other people altogether in order to minimise the risk of being labelled. secrecy can help on the short term to protect individuals from public stigma, but often it has negative long-term consequences such as social isolation, distress and unemployment. disclosure, on the other hand, carries the risk to be discriminated by others, but can reduce the burden of secrecy, lead to support by others and reduce public stigma. in this study investigators aim to evaluate whether a group program run both by people with mental illness (peers) and professionals helps to reduce self-stigma and makes it easier for adolescents to handle the necessary choices related to secrecy versus disclosure.

Eligibility criteria:
inclusion criteria: * at least one self-reported current axis i or axis ii disorder according to dsm-5 (american psychiatric association, 2013), which is not restricted to only substance-related disorder(s) * age 13 to 18 * ability to provide written informed consent * fluid in german (needed for self-report measures) * at least a moderate level of self-reported disclosure-related distress/difficulty (score 4 or higher on the screening item 'in general, how distressed or worried are you in terms of secrecy or disclosure of your mental illness to others?', rated from 1, not at all, to 7, very much) exclusion criteria: * self-reported diagnosis of only a substance- or alcohol-related disorder, without non-substance related current psychiatric comorbidity. we will exclude people who only have a substance-/alcohol-related disorder because the disclosure of these disorders is not the topic of the hop intervention * intellectual disability * organic disorders

Keywords: mental illness adolescents intervention stigma disclosure secrecy
long-term epidemiological follow-up of non-small cell lung cancer in scandinavia

Conditions: Non-Small Cell Lung Cancer

Summary: a study to describe and evaluate patient characteristics and clinical outcomes in subjects with diagnosed non small lung cell cancer in sweden, norway and denmark.


Eligibility criteria:
inclusion criteria: patients with a histologically confirmed diagnosis of nsclc (squamous, adenocarcinoma, not otherwise specified nsclc \[nsclc nos\]) identified in the cancer registers exclusion criteria: * age under 18 years at time of diagnosis
cyclophosphamide in the treatment of associated acquired lipodystrophy syndrome with type 1 diabetes

Conditions: Lipodystrophy Acquired; Type1diabetes

Summary: this study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.

patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes have difficulty in blood glucose management due to the presence of both severe insulin resistance and complete insulin deficiency. it is often necessary to use insulin doses several times that of other children of the same age with type 1 diabetes. since autoimmune response is the main cause of panniculitis associated acquired lipodystrophy syndrome, immunosuppressive agents can suppress immune response, prevent and alleviate the progression of panniculitis and acquired lipodystrophy syndrome, and improve insulin resistance caused by subcutaneous fat deficiency. cyclophosphamide is a classic immunosuppressive agent. this study hopes to improve insulin resistance of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes by cyclophosphamide treatment, thereby reducing insulin dosage and improving glucose metabolism.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody. 2. meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory infiltration. 3. meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset, clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low leptin level and autoantibodies can aid in diagnosis. exclusion criteria: 1. mature and effective treatment methods are available. 2. hiv, hbv and hcv were positive. 3. a the active period of infection. 4. at the active stage of malignant tumors. 5. combination of other fatal diseases. 6. existence of mental and psychological diseases.

Keywords: panniculitis associated acquired generalised lipodystrophy cyclophosphamide